275 related articles for article (PubMed ID: 19442178)
1. Endocannabinoids in the treatment of mood disorders: evidence from animal models.
Bambico FR; Duranti A; Tontini A; Tarzia G; Gobbi G
Curr Pharm Des; 2009; 15(14):1623-46. PubMed ID: 19442178
[TBL] [Abstract][Full Text] [Related]
2. The cannabinoid CB1 receptor and the endocannabinoid anandamide: possible antidepressant targets.
Bambico FR; Gobbi G
Expert Opin Ther Targets; 2008 Nov; 12(11):1347-66. PubMed ID: 18851692
[TBL] [Abstract][Full Text] [Related]
3. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
Gaetani S; Dipasquale P; Romano A; Righetti L; Cassano T; Piomelli D; Cuomo V
Int Rev Neurobiol; 2009; 85():57-72. PubMed ID: 19607961
[TBL] [Abstract][Full Text] [Related]
4. Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment.
Hill MN; Carrier EJ; McLaughlin RJ; Morrish AC; Meier SE; Hillard CJ; Gorzalka BB
J Neurochem; 2008 Sep; 106(6):2322-36. PubMed ID: 18643796
[TBL] [Abstract][Full Text] [Related]
5. Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic-pituitary-adrenal axis.
Hill MN; Ho WS; Sinopoli KJ; Viau V; Hillard CJ; Gorzalka BB
Neuropsychopharmacology; 2006 Dec; 31(12):2591-9. PubMed ID: 16710317
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: drug-discovery strategies.
Janero DR; Vadivel SK; Makriyannis A
Int Rev Psychiatry; 2009 Apr; 21(2):122-33. PubMed ID: 19367506
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of fatty acid amide hydrolase and cb(1) cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling.
Egertová M; Cravatt BF; Elphick MR
Neuroscience; 2003; 119(2):481-96. PubMed ID: 12770562
[TBL] [Abstract][Full Text] [Related]
8. Endocannabinoid signaling in the etiology and treatment of major depressive illness.
Hillard CJ; Liu QS
Curr Pharm Des; 2014; 20(23):3795-811. PubMed ID: 24180398
[TBL] [Abstract][Full Text] [Related]
9. The endocannabinoid system in Huntington's disease.
Pazos MR; Sagredo O; Fernández-Ruiz J
Curr Pharm Des; 2008; 14(23):2317-25. PubMed ID: 18781982
[TBL] [Abstract][Full Text] [Related]
10. Local enhancement of cannabinoid CB1 receptor signalling in the dorsal hippocampus elicits an antidepressant-like effect.
McLaughlin RJ; Hill MN; Morrish AC; Gorzalka BB
Behav Pharmacol; 2007 Sep; 18(5-6):431-8. PubMed ID: 17762511
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacological exploitation of the endocannabinoid system: new perspectives for the treatment of depression and anxiety disorders?].
Saito VM; Wotjak CT; Moreira FA
Braz J Psychiatry; 2010 May; 32 Suppl 1():S7-14. PubMed ID: 20512266
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects.
Jiang W; Zhang Y; Xiao L; Van Cleemput J; Ji SP; Bai G; Zhang X
J Clin Invest; 2005 Nov; 115(11):3104-16. PubMed ID: 16224541
[TBL] [Abstract][Full Text] [Related]
13. Interactions between endocannabinoid and serotonergic systems in mood disorders caused by nicotine withdrawal.
Mannucci C; Navarra M; Pieratti A; Russo GA; Caputi AP; Calapai G
Nicotine Tob Res; 2011 Apr; 13(4):239-47. PubMed ID: 21324836
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoids in depressive disorders.
Poleszak E; Wośko S; Sławińska K; Szopa A; Wróbel A; Serefko A
Life Sci; 2018 Nov; 213():18-24. PubMed ID: 30290188
[TBL] [Abstract][Full Text] [Related]
15. Characterization of serotonin neurotransmission in knockout mice: implications for major depression.
Domínguez-López S; Howell R; Gobbi G
Rev Neurosci; 2012; 23(4):429-43. PubMed ID: 23089640
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of endocannabinoid signaling and the pharmacotherapy of depression.
Mangieri RA; Piomelli D
Pharmacol Res; 2007 Nov; 56(5):360-6. PubMed ID: 17945507
[TBL] [Abstract][Full Text] [Related]
17. The Endocannabinoid System Modulating Levels of Consciousness, Emotions and Likely Dream Contents.
Murillo-Rodriguez E; Pastrana-Trejo JC; Salas-Crisóstomo M; de-la-Cruz M
CNS Neurol Disord Drug Targets; 2017; 16(4):370-379. PubMed ID: 28240187
[TBL] [Abstract][Full Text] [Related]
18. The monoaminergic tripartite synapse: a putative target for currently available antidepressant drugs.
Quesseveur G; Gardier AM; Guiard BP
Curr Drug Targets; 2013 Oct; 14(11):1277-94. PubMed ID: 24020973
[TBL] [Abstract][Full Text] [Related]
19. Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors.
Maione S; De Petrocellis L; de Novellis V; Moriello AS; Petrosino S; Palazzo E; Rossi FS; Woodward DF; Di Marzo V
Br J Pharmacol; 2007 Mar; 150(6):766-81. PubMed ID: 17279090
[TBL] [Abstract][Full Text] [Related]
20. Involvement of the endocannabinoid system in drug addiction.
Maldonado R; Valverde O; Berrendero F
Trends Neurosci; 2006 Apr; 29(4):225-32. PubMed ID: 16483675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
